
Galvus50 mg
Novartis (Bangladesh) Ltd.
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Vildagliptin is not indicated for type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Vildagliptin tablets may be taken with or without food.
| Regimen | Recommended Dose |
|---|---|
| Monotherapy, or combined with metformin, a thiazolidinedione, metformin + sulphonylurea, or insulin | 50 mg twice daily (morning and evening) — total 100 mg/day |
| Combined with a sulphonylurea alone | 50 mg once daily, taken in the morning |
| Moderate to severe renal impairment or end-stage renal disease | 50 mg once daily |
| Hepatic impairment | Not recommended (see Contraindications) |
The maximum recommended daily dose is 100 mg. Missed doses should not be doubled up; the next dose should be taken at the regular scheduled time. Dosage should always be individualized by the prescribing physician based on glycemic response and tolerability.
Adverse effects of Vildagliptin are generally mild and transient. Common and serious effects include:
Patients should seek prompt medical attention for persistent abdominal pain, yellowing of the skin/eyes, unusual fatigue, or unexplained blistering of the skin.
Vildagliptin is contraindicated in patients with:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.